

# Mucopolidosis II Alpha/Beta

Subjects: Genetics & Heredity

Contributor: Rita Xu

Mucopolidosis II alpha/beta (also known as I-cell disease) is a progressively debilitating disorder that affects many parts of the body. Most affected individuals do not survive past early childhood.

Keywords: genetic conditions

---

## 1. Introduction

At birth, children with mucopolidosis II alpha/beta are small and have weak muscle tone (hypotonia) and a weak cry. Affected individuals grow slowly after birth and usually stop growing during the second year of life. Development is delayed, particularly the development of speech and motor skills such as sitting and standing.

Children with mucopolidosis II alpha/beta typically have several bone abnormalities, many of which are present at birth. Affected individuals may have an abnormally rounded upper back (kyphosis), feet that are abnormally rotated (clubfeet), dislocated hips, unusually shaped long bones, and short hands and fingers. People with this condition also have joint deformities (contractures) that significantly affect mobility. Most children with mucopolidosis II alpha/beta do not develop the ability to walk independently. Affected individuals have dysostosis multiplex, which refers to multiple skeletal abnormalities seen on x-ray.

Other features of mucopolidosis II alpha/beta include a soft out-pouching around the belly-button (umbilical hernia) or lower abdomen (inguinal hernia), heart valve abnormalities, distinctive-looking facial features that are described as "coarse," and overgrowth of the gums (gingival hypertrophy). Vocal cords can stiffen, resulting in a hoarse voice. The airway is narrow, which can contribute to prolonged or recurrent respiratory infections. Affected individuals may also have recurrent ear infections, which can lead to hearing loss.

## 2. Frequency

Mucopolidosis II alpha/beta is a rare disorder, although its exact prevalence is unknown. It is estimated to occur in about 1 in 100,000 to 400,000 individuals worldwide.

## 3. Causes

Mutations in the *GNPTAB* gene cause mucopolidosis II alpha/beta. This gene provides instructions for making part of an enzyme called GlcNAc-1-phosphotransferase. This enzyme helps prepare certain newly made enzymes for transport to lysosomes. Lysosomes are compartments within the cell that use digestive enzymes to break down large molecules into smaller ones that can be reused by cells. GlcNAc-1-phosphotransferase is involved in the process of attaching a molecule called mannose-6-phosphate (M6P) to specific digestive enzymes. Just as luggage is tagged at the airport to direct it to the correct destination, enzymes are often "tagged" after they are made so they get to where they are needed in the cell. M6P acts as a tag that indicates a digestive enzyme should be transported to the lysosome.

Mutations in the *GNPTAB* gene that cause mucopolidosis II alpha/beta prevent the production of any functional GlcNAc-1-phosphotransferase. Without this enzyme, digestive enzymes cannot be tagged with M6P and transported to lysosomes. Instead, they end up outside the cell and have increased digestive activity. The lack of digestive enzymes within lysosomes causes large molecules to accumulate there. Conditions that cause molecules to build up inside lysosomes, including mucopolidosis II alpha/beta, are called lysosomal storage disorders. The signs and symptoms of mucopolidosis II alpha/beta are most likely caused by the lack of digestive enzymes within lysosomes and the effects these enzymes have outside the cell.

Mutations in the *GNPTAB* gene can also cause a similar but milder disorder called mucopolipidosis III alpha/beta. Instead of preventing the production of any enzyme, these mutations reduce the activity of GlcNAc-1-phosphotransferase. Mucopolipidosis III alpha/beta and mucopolipidosis II alpha/beta represent two ends of a spectrum of disease severity.

### 3.1. The Gene Associated with Mucopolipidosis II Alpha/Beta

- GNPTAB

## 4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

## 5. Other Names for This Condition

- I-cell disease
- inclusion cell disease
- MLII
- mucopolipidosis II
- mucopolipidosis type II

---

## References

1. Bargal R, Zeigler M, Abu-Libdeh B, Zuri V, Mandel H, Ben Neriah Z, Stewart F, Elcioglu N, Hindi T, Le Merrer M, Bach G, Raas-Rothschild A. When Mucopolipidosis III meets Mucopolipidosis II: GNPTA gene mutations in 24 patients. *Mol Genet Metab*. 2006 Aug;88(4):359-63. Jul;91(3):299.
2. Braulke T, Pohl S, Storch S. Molecular analysis of the GlcNAc-1-phosphotransferase. *J Inher Metab Dis*. 2008 Apr;31(2):253-7. doi:10.1007/s10545-008-0862-5.
3. Cathey SS, Kudo M, Tiede S, Raas-Rothschild A, Braulke T, Beck M, Taylor HA, Canfield WM, Leroy JG, Neufeld EF, McKusick VA. Molecular order in mucopolipidosis II and III nomenclature. *Am J Med Genet A*. 2008 Feb 15;146A(4):512-3. doi:10.1002/ajmg.a.32193.
4. Cathey SS, Leroy JG, Wood T, Eaves K, Simensen RJ, Kudo M, Stevenson RE, Friez MJ. Phenotype and genotype in mucopolipidoses II and III alpha/beta: a study of 61 probands. *J Med Genet*. 2010 Jan;47(1):38-48. doi: 10.1136/jmg.2009.067736.
5. Kudo M, Brem MS, Canfield WM. Mucopolipidosis II (I-cell disease) and mucopolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta -subunits precursor gene. *Am J Hum Genet*. 2006 Mar;78(3):451-63.
6. Leroy JG, Cathey SS, Friez MJ. GNPTAB-Related Disorders. 2008 Aug 26 [updated 2019 Aug 29]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from <http://www.ncbi.nlm.nih.gov/books/NBK1828/>
7. Otomo T, Higaki K, Nanba E, Ozono K, Sakai N. Lysosomal storage causes cellular dysfunction in mucopolipidosis II skin fibroblasts. *J Biol Chem*. 2011 Oct 7;286(40):35283-90. doi: 10.1074/jbc.M111.267930.
8. Otomo T, Muramatsu T, Yorifuji T, Okuyama T, Nakabayashi H, Fukao T, Ohura T, Yoshino M, Tanaka A, Okamoto N, Inui K, Ozono K, Sakai N. Mucopolipidosis II and III alpha/beta: mutation analysis of 40 Japanese patients showed genotype-phenotype correlation. *J Hum Genet*. 2009 Mar;54(3):145-51. doi:10.1038/jhg.2009.3.
9. Plante M, Claveau S, Lepage P, Lavoie EM, Brunet S, Roquis D, Morin C, Vézina H, Laprise C. Mucopolipidosis II: a single causal mutation in the N-acetylglucosamine-1-phosphotransferase gene (*GNPTAB*) in a French Canadian founder population. *Clin Genet*. 2008 Mar;73(3):236-44. doi:10.1111/j.1399-0004.2007.00954.x.
10. Saul RA, Proud V, Taylor HA, Leroy JG, Spranger J. Prenatal mucopolipidosis type II (I-cell disease) can present as Pacman dysplasia. *Am J Med Genet A*. 2005 Jun 15;135(3):328-32.
11. Takanashi J, Hayashi M, Yuasa S, Satoh H, Terada H. Hypomyelination in I-cell disease; MRI, MR spectroscopy and neuropathological correlation. *Brain Dev*. 2012 Oct;34(9):780-3. doi: 10.1016/j.braindev.2011.12.013.

12. Tiede S, Storch S, Lübke T, Henrissat B, Bargal R, Raas-Rothschild A, Braulke T. Mucopolipidosis II is caused by mutations in GNPTA encoding the alpha/betaGlcNAc-1-phosphotransferase. *Nat Med*. 2005 Oct;11(10):1109-12.
  13. Wilcox WR, Wenger DA, Lachman RS, Rimoin DL. Distinguishing Pacman dysplasia from mucopolipidosis II: comment on Saul et al. [2005]. *Am J Med Genet A*. 2005 Jun 15;135(3):333.
- 

Retrieved from <https://encyclopedia.pub/entry/history/show/11761>